The fetal liver lymphoid-primed multipotent progenitor provides the prerequisites for the initiation of t(4;11) MLL-AF4 infant leukemia by Malouf, Camille & Ottersbach, Katrin
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fetal liver lymphoid-primed multipotent progenitor provides
the prerequisites for the initiation of t(4;11) MLL-AF4 infant
leukemia
Citation for published version:
Malouf, C & Ottersbach, K 2018, 'The fetal liver lymphoid-primed multipotent progenitor provides the
prerequisites for the initiation of t(4;11) MLL-AF4 infant leukemia', Haematologica.
https://doi.org/10.3324/haematol.2018.191718
Digital Object Identifier (DOI):
10.3324/haematol.2018.191718
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Haematologica
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
1 
 
The fetal liver lymphoid-primed multipotent progenitor provides the 
prerequisites for the initiation of t(4;11) MLL-AF4 infant leukemia 
 
Running title: The cell-of-origin of MLL-AF4+ infant leukemia 
 
Camille Malouf and Katrin Ottersbach 
 
Author affiliations 
MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK, 
EH16 4UU 
 
Contact information for corresponding authors 
Dr. Camille Malouf 
Dr. Katrin Ottersbach 
MRC Centre for Regenerative Medicine 
University of Edinburgh 
Edinburgh Bioquarter 
5 Little France Drive 
Edinburgh 
EH16 4UU 
UK 
Tel.: +44 131 651 9516 
Fax: +44 131 651 9501 
camille.malouf@ed.ac.uk 
katrin.ottersbach@ed.ac.uk 
 
 
Conflicts of interests 
The authors are have no conflicts of interest to disclose. 
 
Grant Support 
Bloodwise, Kay Kendall Leukaemia Fund, MRC, Cancer Research UK 
 
Word count: 1454 
  
2 
 
t(4;11) MLL-AF4 pro-B acute lymphoblastic leukemia (ALL) is an aggressive 
hematological malignancy that accounts for 50-85% of infant ALL cases.1 
Retrospective analysis of Guthrie cards and twin concordance studies both confirmed 
the pre-natal origin of this disease.2 Patients show an accumulation of immature pro-
B cells in the bone marrow, followed by a rapid and uncontrolled proliferation of 
leukemia blasts that hijack the immune system and invade peripheral organs such as 
the spleen, liver and central nervous system. The chromosomal translocation results 
in the fusion of the N-terminal part of MLL with almost the entire AF4 gene, which 
disrupts the epigenetic signature of hematopoietic cells.3 This induces a stem cell-like 
expression signature (e.g. HOXA cluster, MEIS1, RUNX1) as well as a pro-survival 
and proliferation phenotype (characterized by the upregulation of BCL2, MCL1, 
CDK6).4-8  
The molecular signature at diagnosis has been well characterized, but 
information on the initial changes during the first stages of leukemogenesis is lacking 
due to the challenge posed by the pre-natal origin of the disease. We recently 
described a pre-leukemia model of t(4;11) MLL-AF4 infant leukemia, which uses an 
Mll-AF4 invertor line and a VE-Cadherin-driven Cre recombinase to target the 
expression of Mll-AF4 to all definitive hematopoietic cells formed during embryonic 
development.9 While this model does not progress to the same rapid, acute leukemia 
phenotype observed in human patients, possibly due to species differences,10 it 
provides unique access to the prenatal pre-leukemic state in vivo. Mll-AF4 expression 
was shown to lead to increased engraftment and self-renewal potential of E14 fetal 
liver (FL) cells, as well as a high B lymphoid clonogenic potential; however, the precise 
contribution from individual cell types was not addressed in detail.  
Here, we separated the hematopoietic compartment into three stem/progenitor 
fractions, HSC/MPPs, LMPPs and LK/CLPs, with a sorting strategy adapted to the 
fetal context (Figure S1A),11 and used transplantation assays and gene expression 
analysis to further characterize the cell-of-origin of t(4;11) MLL-AF4 pro-B ALL. 
Extensive details on the material and methods can be found in the supplementary 
section.  Analysis of cell cycle distribution showed that the HSC/MPP population was 
more highly represented in the G0-G1 phase compared to LMPP and LK/CLP (Figure 
S1B), and less in the G2/M phase (Figure S1C). Mll-AF4 did not alter the cell cycle 
distribution of HSC/MPPs, LMPPs or LK/CLPs, suggesting that proliferation is not 
hijacked during early stages of leukemogenesis.  
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All three fractions were transplanted to assess their engraftment, self-renewal 
and differentiation potentials. Mll-AF4 did not affect the engraftment of HSC/MPPs or 
LK/CLPs, but led to a significantly higher engraftment of the LMPP fraction (Figure 1A-
C). We previously found that HSC/MPPs and LMPPs from E14 FL could form B-
lymphoid colonies with a pro-B phenotype when Mll-AF4 is expressed.9 We therefore 
assessed the lineage output in the peripheral blood of the primary recipients. While 
there was no difference in T (CD3+) and mature B cell (B220+CD19+IgM+) production, 
LMPPs had a lower myeloid (CD11b+Gr1+) and higher immature B cell 
(B220+CD19+IgM-) output compared with HSC/MPPs (Figure 1D). This skewing was, 
however, independent of Mll-AF4 expression and therefore represents an intrinsic 
property of LMPPs. Mll-AF4+ LMPP primary recipients had the highest white blood 
cell count one month after transplant, suggesting a faster contribution to the 
hematopoietic system (Figure 1E); however, this difference diminished over time. The 
expression of Mll-AF4 is significantly higher in E14 fetal liver LMPPs compared to 
HSC/MPPs and LK/CLPs, which may offer an explanation for their enhanced 
engraftment in primary recipients (Figure 1F, left set of graphs).  
We then assessed the self-renewal potential of HSC/MPPs and LMPPs in 
secondary transplantations. Mll-AF4 expression increased the repopulation of 
secondary recipients with HSC/MPPs compared with the Mll-AF4- control (Figure 1G), 
although engraftment levels were not significantly different from those observed with 
Mll-AF4+ HSC/MPPs in primary recipients (Figure S1D). Mll-AF4+ LMPPs, on the 
other hand, only showed limited self-renewal (Figure 1G), suggesting that Mll-AF4 can 
only enhance self-renewal in cells that already possess this property. Furthermore, we 
detected an upregulation of Mll-AF4 expression following transplantation in 
HSC/MPPs sorted from primary recipients, while it remained unchanged in LMPPs, 
which may also contribute to the higher self-renewal potential of Mll-AF4+ HSC/MPPs 
(Figure 1F, right set of graphs). Both populations displayed skewing towards the B 
lineage in the presence of Mll-AF4 in secondary recipients, which, in the case of 
LMPPs, resulted in an almost entirely B lymphoid-biased output (Figure 1H). The white 
blood cell count was significantly higher in Mll-AF4+ HSC/MPP secondary recipients 
from two months after transplantation (Figure 1I). 
We did a post-mortem analysis of HSC/MPP secondary recipients and LMPP 
primary recipients (6-15 months old). As shown above, hematopoietic progenitors 
such as LMPPs, can only engraft primary recipients, whereas HSCs can serially 
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engraft. Therefore, we compared LMPP primary recipients and HSC/MPP secondary 
recipients to assess differences in hematopoietic output established by HSCs and 
LMPPs. Mll-AF4+ HSC/MPPs and LMPPs showed a significantly higher engraftment 
in the bone marrow and liver compared to Mll-AF4- HSC/MPPs (Figure 1J). 
Furthermore, LMPP primary recipients had more donor cells in the spleen compared 
to Mll-AF4+ HSC/MPP recipients. While there were no significant differences in the 
stem/progenitor compartment in the bone marrow (Figure 1K), Mll-AF4+ LMPP 
primary recipients displayed a trend towards more pro-B cells in the spleen compared 
to Mll-AF4+ HSC/MPP secondary recipients (Figure 1L), which resulted in a higher 
proportion of mature B220+CD19+IgM+ cells (Figure 1M).  
To explain the cell type-specific effects, we assessed the expression of 14 
genes associated with t(4;11) MLL-AF4 pro-B ALL and, more specifically, linked to 
HSC signature, B-lymphoid differentiation, cell division and pro-survival phenotypes: 
Flt312, Meis14, Hoxa94, Hmga213, Lmo214, Runx15, Cdk68, 15, Il7r16, Pax516, Ikaros16, 
E2a16, Bcl-27, Mcl17 and Twist16 (Figure 2A). Flt3 is upregulated in LMPPs regardless 
of Mll-AF4 status (Figure 2B), while Meis1 is upregulated specifically in response to 
Mll-AF4 expression in LMPPs (Figure 2C). The expression of Hoxa9 in Mll-AF4+ 
LMPPs is significantly higher compared with Mll-AF4+ HSC/MPPs and/or Mll-AF4+ 
LK/CLPs (Figure 2D). Hmga2, Lmo2 and Runx1 expression in Mll-AF4+ LMPPs is 
significantly higher compared with Mll-AF4+ HSC/MPPs and/or Mll-AF4+ LK/CLPs 
(Figure 2E-G). Cdk6 expression was higher in LK/CLPs, and decreased in HSC/MPPs 
upon Mll-AF4 expression (Figure 2H). This can partly explain the enhanced self-
renewal of Mll-AF4+ HSC/MPPs compared to Mll-AF4- HSC/MPPs (Figure 1G). The 
expression of IL7r and Pax5 was generally higher in LMPPs, but was not significantly 
affected by Mll-AF4 expression, although there was a clear trend (Figure 2I,J), 
whereas Ikaros and E2a were strongly upregulated in Mll-AF4+ LMPPs compared to 
Mll-AF4- LMPPs and Mll-AF4+ HSC/MPPs and LK/CLPs (Figure 2K,L). This likely 
explains the strong B-lymphoid bias observed in the transplant recipients (Figure 1H). 
We observed a significant upregulation of Bcl-2 in Mll-AF4+ LMPPs compared to Mll-
AF4- LMPPs (Figure 2M), which is a direct transcriptional target of MLL-AF4.7 Mcl1 
expression was relatively stable (Figure 2N), but Twist1 was upregulated in Mll-AF4+ 
LMPP compared to HSC/MPP and LK/CLP Mll-AF4+ cells (Figure 2O). We assessed 
the expression of Flt3, Meis1, Hoxa9, E2a and Bcl-2 in sorted Mll-AF4+ HSC/MPPs, 
LMPPs and LK/CLPs from primary recipients to measure expression changes induced 
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by transplantation stress and a change in microenvironment: FL versus bone marrow 
(Figure 2B,C,D,L,M). The relative expression pattern amongst the three populations 
was similar in freshly sorted FL cells and sorted cells from primary recipients. 
However, there is a general upregulation of Flt3, Meis1, Hoxa9 and E2a in cells from 
primary recipients (Figure 2B,C,D,L), which may explain the shorter disease latency 
following transplantation observed previously.9 The strong upregulation of E2a also 
likely explains the strong B lymphoid bias observed in LMPP recipients (Figure 1H). 
This study suggests that the FL LMPP sets the stage for the transformation process 
of t(4;11) MLL-AF4 infant pro-B ALL through the higher expression of Flt3, Hoxa9, 
Lmo2, Runx1, Il7r, Pax5, E2a and Twist1 (Figure 2P). The activation of Mll-AF4 
increases the expression of E2a, Ikaros, Meis1 and Bcl-2, leading to a strong B 
lymphoid bias and a survival advantage. This study is a step forward in understanding 
the molecular mechanisms of infant leukemogenesis, and also further supports our 
previous proposition that the FL LMPP is the cell-of-origin of t(4;11) Mll-AF4 pro-B 
ALL. 
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Figure legends 
 
Figure 1. In the presence of Mll-AF4, E14 FL LMPPs display higher engraftment 
potential and a B-lymphoid bias. (A-C) Primary transplant of 1000 HSC/MPPs (A), 
750 LMPP (B) and 1000 LK/CLP (C). Total donor chimerism in peripheral blood is 
shown and dotted line represents 5% threshold for considering mice as being 
repopulated. Repopulated mice/total injected shown next to the curve. (D) Donor 
chimerism in individual lineages of primary recipients 4 months after transplant. (E) 
White blood cell count in the peripheral blood of primary recipients. (F) Quantitative 
PCR of Mll-AF4 in fresh fetal liver HSC/MPP, LMPP and LK/CLP and sorted cells from 
primary recipients. (G) Secondary transplant of HSC/MPP and LMPP-derived bone 
marrow cells from primary recipients. (H) Donor chimerism in individual lineages of 
secondary recipients 4 months after transplant. (I) White blood cell count in the 
peripheral blood of secondary recipients. (J) Donor chimerism in the peripheral blood, 
bone marrow, spleen and liver at end of study. (K) Donor-derived HSCs, LMPPs, CLP 
and LK in the bone marrow at end of study. (L) Donor-derived pre-pro-B and pro-B 
cells in the bone marrow and spleen at end of study. (M) Donor chimerism in individual 
lineages at end of study. A non-parametric Mann-Whitney test was used to compare 
datasets with a significance cut-off of p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) or p < 
0.0001 (****). 
 
Figure 2. The LMPP population displays an MLL-AF4 gene expression signature. 
(A) Quantitative PCR strategy in fresh fetal liver cells (n = 6-7) and cells derived from 
primary recipients (n = 3). Quantitative PCR of (B) Flt3, (C) Meis1, (D) Hoxa9, (E) 
Hmga2, (F) Lmo2, (G) Runx1 (H) Cdk6, (I) Il7r, (J) Pax5, (K) Ikaros, (L) E2a, (M) Bcl2, 
(N) Mcl1, (O) Twist1. (P) Early stages of t(4;11) MLL-AF4 infant leukemia based on 
the pre-leukemia mouse model. A non-parametric Mann-Whitney test was used to 
compare datasets with a significance cut-off of p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***) or p < 0.0001 (****). 


Supplementary Material and Methods 
 
Mice 
The animal work was done under regulation of the UK Home Office. Males and 
females from the Mll-AF41 and the VEC-Cre2 line were mated to obtain Mll-AF4-
expressing embryos. The day of the plug was counted as day 0 of embryonic 
development.  
 
Cell sorting of HSC/MPP, LMPP and LK/CLP populations 
The fetal liver was dissected and dissociated in Flow Cytometry Staining Buffer 
(ThermoFisher Cat# 00-4222-26) using a 21Gx15mm needle attached to a syringe 
(BD Microlance Cat# 10472204-X, BD Cat# 3000185). Cells were stained using the 
following antibody mix in Flow Cytometry Staining Buffer: APC anti-mouse CD3ε 
antibody (clone I45-2C11, Biolegend Cat# 100312), APC anti-mouse TER-119 
antibody (clone TER119, Biolegend Cat# 116212), APC anti-mouse F4/80 antibody 
(clone BM8, Biolegend Cat# 123116), APC anti-mouse Nk1.1 antibody (clone PK136, 
Biolegend Cat# 108709), APC anti-mouse Ly-6G/Ly-6C (Gr-1) antibody (clone RB6-
8C5, Biolegend Cat# 108412), PE/Cy7 anti-mouse/human CD45R/B220 antibody 
(clone RA3-6B2, Biolegend Cat# 103222), PE/Cy7 anti-mouse CD19 antibody (clone 
6D5, Biolegend Cat# 115520), APC-eFluor 780 CD117 (ckit) antibody (clone 2B8, 
ThermoFisher Cat# 47-1171-80), Alexa Fluor® 700 anti-mouse CD45 antibody (clone 
30-F11, Biolegend Cat# 103128), Pacific Blue™ anti-mouse Ly-6A/E (Sca-1) antibody 
(Clone E13-161.7, Biolegend Cat# 122519), PE anti-mouse CD127 antibody (clone 
A7T34, ThermoFisher Cat# 12-1271-82), biotin anti-mouse CD135 (Flt3) antibody 
(clone A2F10, ThermoFisher Cat# 13-1351-81). Cells were stained for 20 minutes on 
ice and washed once with Flow Cytometry Staining Buffer. Cells were then 
resuspended in diluted Qdot 655 Streptavidin Conjugate (ThermoFisher Cat# 
Q10123MP) and incubated for 20 minutes on ice. Cells were washed once and 
resuspended in diluted SYTOXTM Green Nucleic Acid Stain (ThermoFisher Cat# 
S7020) to exclude dead cells. Sorting was done on a BD FACSAriaTM II (BD 
Biosciences). 
 
 
Transplantation of CD45.1/2 mice with HSC/MPP, LMPP and LK/CLP 
On the day of transplant, recipient mice (CD45.1/2) received two doses of 4.6 Gy at a 
3 hours interval. Donor cells (CD45.2/2) were injected through the tail vein along with 
bone marrow helper cells (CD45.1/1). For HSC/MPP transplants, we used 100 000 
helper cells and for LMPP and LK/CLP, we used 20 000 helper cells. Mice were 
administered antibiotics after transplantation through their drinking water (0.1 mg/mL 
enrofloxacin, 10% Baytril solution from Bayer). For secondary transplants, the number 
of bone marrow cells transplanted was adjusted according to the repopulation in 
primary recipient (85% repopulation in primary recipient, 2 x 106 total bone marrow 
cells injected). Mice were bled on a monthly basis, and blood counts were measured 
on a Celltac MEK-6500K (Nihon Kohden). Red blood cell lysis was achieved with BD 
Pharm Lyse™ lysing solution according to the manufacturer’s instructions (BD 
Biosciences Cat# 555899). Cells were stained in Flow Cytometry Staining Buffer using 
the following antibodies: FITC CD45.2 antibody, (clone 104, ThermoFisher Cat# 11-
0454-81), APC-eFluor 780 CD45.1 monoclonal antibody (clone A20, ThermoFisher 
Cat# 47-0453-80), eFluor450 CD11b monoclonal antibody (clone M1/70, 
ThermoFisher Cat# 48-0112-80), Alexa Fluor® 700 Ly-6G/Ly-6C (Gr-1) antibody 
(clone RB6-8C5, Biolegend Cat# 108422), PE/Cy7 CD45R/B220 antibody (clone RA3-
6B2, Biolegend, Cat# 103222), Brilliant Violet 605™ CD19 antibody (clone 6D5, 
Biolegend Cat# 115539), APC mouse IgM monoclonal antibody (clone II/41, 
ThermoFisher Cat# 17-5790-82), PE CD3e (clone 145-2C11, Biolegend Cat# 
100308). For sorting/analysis of hematopoietic stem and progenitor cells in organs 
and analysis of B cell populations in primary and secondary recipients, we used the 
following antibodies: the APC lineage cocktail from the sorted E14 FL cells, FITC 
CD45.2 antibody, (clone 104, ThermoFisher Cat# 11-0454-81), APC-eFluor 780 
CD45.1 monoclonal antibody (clone A20, ThermoFisher Cat# 47-0453-80), Brilliant 
Violet 421TM CD117 (c-Kit) antibody (clone 2B8, Biolegend Cat# 105827), APC-eFluor 
780 CD117 antibody (clone 2B8, ThermoFisher 47-1171-82), PE/Cy7 Ly6A/E (Sca-1) 
antibody (clone E13-161.7, Biolegend Cat#122513), PB Sca1 antibody (clone E13-
161.7, Biolegend, Cat# 47-1171-82), PerCP/Cy5.5 CD34 antibody (clone HM34, 
Biolegend, Cat# 128607), PE CD135 antibody (clone A2F1, Biolegend, Cat# 135306), 
biotin anti-mouse CD135 (Flt3) antibody (clone A2F10, ThermoFisher Cat# 13-1351-
81), Alexa Fluor® 700 CD48 antibody (clone HM48-1, Biolegend, Cat# 103425), 
PE/Cy7 CD150 antibody (clone TC15-12F12.2, Biolegend, Cat# 115914), Alexa 
Fluor® 700 CD45R/B220 antibody (clone RA3-6B2, Biolegend, Cat# 103232), PE/Cy7 
CD19 antibody (clone 6D5, Biolegend, Cat# 115520), PerCP CD43 antibody (clone 
1B11, Biolegend, Cat# 121222), Brilliant Violet 421TM CD24 antibody (clone M1/69, 
Biolegend, Cat# 101825), APC CD127 antibody (clone A7R34, Biolegend, Cat# 
135011). Cells were incubated on ice for 20 minutes, washed twice with Flow 
Cytometry Staining Buffer and resuspended in diluted SYTOX AADvanced 
(ThermoFisher, Cat# S10274) to exclude dead cells. Data was acquired on a BD 
LSRFortessaTM (BD Biosciences). For end of study analysis, cell types were identified 
as follows: HSCs (LSK CD34+/- FLT3- CD150+ CD48-), LMPPs (LSK CD34+/- 
FLT3+), CLP (Lin- ckitlow Sca1low IL7R+ FLT3+), LK (Lin- ckit+ Sca1-), pre-pro-B 
(CD45.2+ ckit- CD43+ CD24low B220+ CD19-) and pro-B (CD45.2+ ckit+ CD43+ 
CD24+ B220+ CD19+). 
 
Cell Cycle  
Sorted HSC/MPP, LMPP and LK/CLP cells were collected in Flow Cytometry Staining 
Buffer and an equivalent volume of 5 μg/mL DAPI 1% IGEPAL (Sigma-Aldrich D9542 
and CA-630) solution was added. Cells were incubated at room temperature for 1 
minute, in the dark. Data was acquired on a BD LSRFortessaTM (BD Biosciences). 
 
RNA extraction, reverse transcription and quantitative PCR 
RNA extraction and reverse transcription were performed using the RNeasy Micro Kit 
(QIAGEN Cat# 74004) and iScript Ready-to-Use cDNA Supermix (Bio-Rad 
Laboratories Ltd Cat# 1708841) according to the manufacturer’s instructions. Primer 
sequences are: Flt3.F/R (gccagttcagcccgccta/agattccctcggactggtgc), Meis1.F/R 
(attcacactgctggagacgc/cgtcgtacctttgcgccatc), Cdk6.F/R 
(ccaacgtggtcaggttgttt/gccgggctctggaactttat), Mcl1.F/R 
(agaggctgggatgggtttgt/ccctattgcactcacaaggc), Twist1.F/R 
(gccggagacctagatgtcatt/ccacgccctgattcttgtga), Runx1.F/R 
(ttcgcagagcggtgaaagaa/tgctgtctgaagccatcgtt), Hoxa9.F/R 
(ccacgcttgacactcacact/cagccgggttattgggatcg), Hmga2.F/R 
(gcctgctcaggagactgaag/ggaagtagaaagaccgtggca), Bcl2.F/R 
(ggaggctgggatctttgt/acttgtggcaggtatgc), Lmo2.F/R 
(ctggacccgtctgaggaac/gacacccacagaggtcacag), Ikaros.F/R 
(ccctgaggacctgtccactac/acgcccattctcttcatcac), Il7r.F/R 
(cgaaactccagaacccaaga/aatggtgacacttggcaagac), E2a.F/R 
(aagaggacaagaaggacctgaa/ttattggccatacgcctctc), Pax5.F/R 
(accatcaggacaggacatgg/gcggactacatctgggagtg), Mll-AF4 F/R 
(agtgggcatgtagagggatc/atggctcagctgtactaggc) and beta-actin F/R 
(tcctgtcctcactgtcca/gtccgcctagaagcacttgc). Quantitative PCR was carried out with 
Brilliant III Ultra-Fast SYBR QPCR (Agilent Technologies Cat#600883) according to 
the manufacturer’s instructions. Data was acquired on a QuantStudioTM 7 Flex Real-
Time PCR System (ThermoFisher). 
 
 
Data analysis, statistics and graphs 
Analysis of flow cytometry data was performed with FlowJo (version 10) and graphs 
were generated with GraphPad Prism (version 6). Statistical analysis was performed 
with GraphPad using a non-parametric t test (Mann-Whitney) with a bi-lateral p-value. 
Data are presented as Mean ± SEM. 
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Supplementary Figure 1 
 
 
 
 
 
Figure S1. Sorting strategy and cell cycle analysis of E14FL HSC/MPP, LMPP 
and LK/CLP cells (A) Sorting strategy of E14 FL HSC/MPP (Lin- B220- CD19- CD45+ 
ckit+ Sca1high IL7R- Flt3-), LMPP (Lin- B220- CD19- CD45+ ckit+ Sca1high Flt3+) 
and LK/CLP (Lin- B220- CD19- CD45+ ckit+ Sca1low/-). (B,C) Cell cycle analysis (n 
= 5-7). HSC – hematopoietic stem cell, MPP – multipotent progenitor, LMPP - 
lymphoid-primed multipotent progenitor, LK – Lin- ckit+, CLP – common lymphoid 
progenitor. (D) Repopulation of Mll-AF4+ VEC-Cre+ E14 FL HSC/MPPs in primary 
and secondary recipients. 
